Literature DB >> 29544756

Cervical Lymph Node Metastatic Status and Adjuvant Therapy Predict the Prognosis of Salivary Duct Carcinoma.

Kai Qian1, Lu Di2, Kai Guo1, Xiaoke Zheng1, Qinghai Ji3, Zhuoying Wang4.   

Abstract

PURPOSE: Salivary duct carcinoma (SDC) is an aggressive malignancy that is not yet fully understood. We designed the present retrospective study to investigate the factors affecting the prognosis of SDC and the effects of adjuvant therapies on the clinical outcomes of patients.
MATERIALS AND METHODS: Patients with SDC treated surgically from 2006 to 2016 were enrolled in the present retrospective cohort study. The demographic data, clinical pathologic characteristics, and follow-up results were recorded. The prognostic indicators of overall survival (OS), locoregional failure-free survival (LRFFS), and distant metastasis-free survival (DMFS) were analyzed using the Kaplan-Meier method and the Cox proportional hazard model.
RESULTS: The study sample included 66 patients, most of whom were male (81.8%). The 5-year OS, LRFFS, and DMFS for all patients was 52.5%, 63.9%, and 51.3%, respectively. Univariate analysis showed that stage N2-N3, lymph node involvement of levels IV and V, 8 or more positive lymph nodes, and extranodal extension were all negative prognostic indicators for OS. The only significant indicator on multivariate analysis was the number of positive lymph nodes. Multivariate analysis revealed that extracapsular invasion and no adjuvant radiotherapy were risk factors for LRFFS. In contrast, lesions involving both glands and 8 or more positive lymph nodes were prognostic factors for DMFS. Further subgroup analysis showed that radiotherapy was only useful for patients with locally advanced lesions for local control.
CONCLUSIONS: Cervical lymph node metastatic status is an important factor in predicting the prognosis of SDC patients. Adjuvant radiotherapy is useful for local control, especially for patients with stage T4 disease but does not benefit OS and DMFS.
Copyright © 2018 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29544756     DOI: 10.1016/j.joms.2018.01.033

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  4 in total

1.  Oncological outcomes of patients with salivary gland cancer treated with surgery and postoperative intensity-modulated radiotherapy: a retrospective cohort study.

Authors:  Shoumei Zang; Meiqin Chen; Huijie Huang; Xinli Zhu; Xinke Li; Danfang Yan; Senxiang Yan
Journal:  Quant Imaging Med Surg       Date:  2022-05

2.  Radiotherapy as salvage treatment of salivary duct carcinoma in major salivary glands without radical operations.

Authors:  Lu Di; Kai Qian; Chengrun Du; Chunying Shen; Ruiping Zhai; Xiayun He; Xiaoshen Wang; Tingting Xu; Chaosu Hu; Hongmei Ying
Journal:  Cancer Manag Res       Date:  2018-11-21       Impact factor: 3.989

3.  Adjuvant Treatment of the Salivary Duct Carcinoma with Her2 Overexpression.

Authors:  Jelena Berendika; Saša Jungić; Biljana Tubić; Gordana Malčić Kecman; Ivanka Rakita; Zdenka Gojković; Milka Vještica; Gordan Nikić; Božana Babić
Journal:  Case Rep Oncol       Date:  2021-03-29

4.  Prognosis Value of Platelet Counts, Albumin and Neutrophil-Lymphocyte Ratio of Locoregional Recurrence in Patients with Operable Head and Neck Squamous Cell Carcinoma.

Authors:  Jing Ye; Bing Liao; Xiaohua Jiang; Zhihuai Dong; Sunhong Hu; Yuehui Liu; Mang Xiao
Journal:  Cancer Manag Res       Date:  2020-01-31       Impact factor: 3.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.